Nautilus Biotechnology Sees Unusually Large Options Volume (NASDAQ:NAUT)

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) was the recipient of some unusual options trading activity on Monday. Traders acquired 3,253 call options on the stock. This represents an increase of approximately 1,427% compared to the average daily volume of 213 call options.

Institutional Trading of Nautilus Biotechnology

A number of institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC bought a new stake in shares of Nautilus Biotechnology during the 2nd quarter valued at $63,000. Corient Private Wealth LP boosted its position in shares of Nautilus Biotechnology by 43.6% in the 2nd quarter. Corient Private Wealth LP now owns 164,788 shares of the company’s stock worth $308,000 after purchasing an additional 50,000 shares during the last quarter. TD Waterhouse Canada Inc. boosted its position in shares of Nautilus Biotechnology by 1,500.0% in the 2nd quarter. TD Waterhouse Canada Inc. now owns 16,000 shares of the company’s stock worth $29,000 after purchasing an additional 15,000 shares during the last quarter. AXQ Capital LP acquired a new stake in shares of Nautilus Biotechnology during the second quarter worth $64,000. Finally, Susquehanna International Group LLP increased its holdings in Nautilus Biotechnology by 1,710.9% in the second quarter. Susquehanna International Group LLP now owns 890,949 shares of the company’s stock valued at $1,666,000 after purchasing an additional 841,749 shares during the last quarter. Institutional investors and hedge funds own 50.71% of the company’s stock.

Nautilus Biotechnology Trading Down 5.3%

Nautilus Biotechnology stock opened at $1.77 on Wednesday. Nautilus Biotechnology has a 1 year low of $0.82 and a 1 year high of $4.31. The company has a market cap of $225.23 million, a PE ratio of -3.93 and a beta of 0.73. The company’s 50-day moving average is $1.03 and its two-hundred day moving average is $2.00.

Nautilus Biotechnology (NASDAQ:NAUT) last issued its quarterly earnings results on Monday, July 27th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.03. The business had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.10 million. Research analysts forecast that Nautilus Biotechnology will post -0.52 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Zacks Research raised shares of Nautilus Biotechnology to a “hold” rating in a research note on Wednesday, September 30th. Leerink Partners started coverage on shares of Nautilus Biotechnology in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $4.00 price objective for the company. Weiss Ratings downgraded Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 5th. Finally, Roth Capital began coverage on Nautilus Biotechnology in a research report on Tuesday, September 29th. They issued a “buy” rating and a $3.50 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $3.83.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc is a life sciences technology company developing tools for large-scale protein analysis. Its goal is to enable more comprehensive, sensitive and efficient study of the proteome, the full set of proteins expressed by a biological system, to support research in drug discovery, disease biology and translational science.

The company’s primary offering is the Nautilus Proteome Analysis Platform, which combines a proprietary analytical instrument, consumables and software.